Liu Y, et al. - Via a systematic review and meta-analysis of randomized controlled trials, researchers sought to assess lebrikizumab as a treatment option for treating patients with uncontrolled asthma, focusing on its efficacy and safety. They analyzed five trials from PubMed, Embase, Web of Science and Cochrane, with outcomes of interest being the rate of asthma exacerbations, relative changes in the forced expiratory volume in the first second of expiration (FEV₁) of predicted value (%) and incidence of adverse events. They found that, a significant reduction in the rate of exacerbation as well as an improvement of lung function resulted from lebrikizumab treatment in patients with uncontrolled asthma. These benefits were observed especially in patients with high periostin levels. In terms of the incidence of adverse events related to lebrikizumab treatment, no significant difference was observed when compared with placebo.